India's Richest People 2026 edition · 1 director · Source: Hurun India
- #102 Kiran Mazumdar-Shaw ₹32,900 Cr
Revenue · FY 2025
₹10,144 Cr
▲ 13% YoY
Net profit · FY 2025
₹889.6 Cr
Net margin 8.8%
EBITDA · FY 2025
₹3,108 Cr
EBITDA margin 30.6%
Authorised capital
₹3,500 Cr
Registered with MCA
Paid-up capital
₹1,819.87 Cr
Issued & subscribed
Open charges
₹9,543.66 Cr
Satisfied ₹18,987 Cr
Company age
10 yrs
Est. 2016
Employees · EPFO
5,280
Provident fund records
About Biocon Biologics Limited
Data last updated:
Biocon Biologics Limited is a public limited company based in Bengaluru, Karnataka, India, a subsidiary of Biocon Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 08 June 2016 and has been in existence for over 10 years.
Its director Kiran Mazumdar-Shaw is #102 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24119KA2016PLC093936. Its GSTIN is 29AAGCB7796M2ZO (Karnataka). The company holds 21 GST registrations, of which 19 are active.
The company has an authorised share capital of ₹3,500 Cr and a paid-up capital of ₹1,819.87 Cr. It was formerly known as Biocon Biologics India Limited. It is led by directors including Kiran Mazumdar Shaw (Whole-Time Director) and Bobby Kanubhai Parikh.
Its last annual general meeting (AGM) was held on 25 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Biocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – II Hosur Road, Bengaluru, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹10,144 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹889.6 Cr (net margin 8.8%) and EBITDA of ₹3,108 Cr (EBITDA margin 30.6%). Revenue has grown at a compounded annual rate (CAGR) of 43% over three years and 34% over five years.
The company has about 5,280 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹9,543.66 Cr and satisfied charges of ₹18,987 Cr on record. Court records list 42 cases involving the company, including 38 filed by the company and 4 filed against it; 12 cases are pending. The company has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025. Its 10 peer companies in the Pharma industry (API Manufacturers, Biologics), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 34 MSME Form 1 returns on record between 2019 and 2024, listing 28,937 overdue payments to 1,111 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.
Company details
CIN U24119KA2016PLC093936
Registration Number 093936
Incorporation Date 08 June 2016
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 25 July 2025
Date of Balance Sheet 31 March 2025
Parent Company Biocon Limited
Compliance Status Active Compliant
CIN history
Biocon Biologics has one previous CIN (Corporate Identification Number): U24119KA2016FLC093936. The current CIN is U24119KA2016PLC093936, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24119KA2016PLC093936 | Current |
| U24119KA2016FLC093936 | Previous |
Key People
Shreehas Pradeep Tambe Ceo Kiran Mazumdar Shaw Whole-Time Director Bobby Kanubhai Parikh Director Recognitions & Rankings of Biocon Biologics
Contact details
Biocon Biologics Limited's registered office is in Bengaluru, Karnataka. Its website is biocon.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressBiocon House Ground Floor Tower – 3 Semicon Park Electronic City Phase – II Hosur Road, Bengaluru, Karnataka, India – 560100
- IndustryPharma, API Manufacturers
To see the full contact details of Biocon Biologics Limited, buy the company report.
Comprehensive company report
Biocon Biologics Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Biocon Biologics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Biocon Biologics Limited, buy the company report.
Financials of Biocon Biologics Limited
FY 2025 filings availableBiocon Biologics Limited reported revenue of ₹10,144 Cr (up 13% YoY) for FY 2025.
Revenue · FY 2025
₹10,144 Cr ▲ 13%
Net profit · FY 2025
₹889.6 Cr margin 8.8%
EBITDA · FY 2025
₹3,108 Cr margin 30.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 13%
3 years · compounded
▲ 43%
5 years · compounded
▲ 34%
EBITDA CAGR growth
1 year
▲ 41%
3 years · compounded
▲ 49%
5 years · compounded
▲ 32%
Revenue has grown at a compounded annual rate (CAGR) of 34% over five years, including 13% growth in the latest year. EBITDA rose 41% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3,108 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹889.6 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 30.6% | ||||
| Net Profit Margin | 8.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Biocon Biologics Limited, buy the company report.
Board of directors and KMP of Biocon Biologics Limited
Biocon Biologics Limited currently reports 8 directors and 1 key managerial person. 22 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bobby Kanubhai Parikh Also directs: Avaana Capital Advisors LLP, Hindustan Unilever Limited, Indostar Capital Finance Limited and 4 more | Director | 01 Aug 2019 | 7 Years 3 Months | Current |
| Kiran Mazumdar Shaw | Whole-Time Director | 08 Jun 2016 | 10 Years 4 Months | Current |
| Daniel Mark Bradbury Also directs: Biocon Limited | Director | 01 Aug 2019 | 7 Years 3 Months | Current |
| Rajiv Malik | Nominee Director | 29 Nov 2022 | 3 Years 11 Months | Current |
| Peter Baron Piot Also directs: Biocon Limited, Biological E. Limited | Director | 21 Jan 2021 | 5 Years 9 Months | Current |
| Shreehas Pradeep Tambe Also directs: Biocon Limited | Ceo | 05 Dec 2022 | 3 Years 10 Months | Current |
Showing 6 of 9 current directors and KMP. View all directors and KMP
Peer comparison
Biocon Biologics Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Biologics), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹54,543 Cr (FY 2025) | 9.0% | Vadodara, Gujarat, India | |||
| Cipla Limited | ₹28,409 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Lupin Limited | ₹22,904 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Hetero Labs Limited | ₹16,537 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Glenmark Pharmaceuticals Limited | ₹13,435 Cr (FY 2025) | 6.0% | Mumbai, Maharashtra, India | |||
| Biocon Biologics Limitedthis company | ₹10,144 Cr (FY 2025) | ₹889.6 Cr | 8.8% | 13.0% | 5,280 | Bengaluru, Karnataka, India |
| Divi's Laboratories Limited | ₹9,712 Cr (FY 2025) | 19.0% | Hyderabad, Telangana, India | |||
| Macleods Pharmaceuticals Ltd | ₹9,671.68 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Ipca Laboratories Limited | ₹9,032.39 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Deccan Fine Chemicals (India) Private Limited | ₹8,738.51 Cr (FY 2024) | -1.0% | Hyderabad, Telangana, India | |||
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | 19.0% | Pune, Maharashtra, India |
To see the full peer comparison of Biocon Biologics Limited, buy the company report.
Auditor
Biocon Biologics Limited is audited by B S R & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| B S R & Co. LLP | FY 2023 | 101248W/W-100022 |
Shareholding
The shareholding of Biocon Biologics Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Biocon Biologics Limited, buy the company report.
Charges & borrowings
Open charges
₹9,543.66 Cr
Satisfied charges
₹18,987 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 09 Dec 2024 | 101019160 | Others | ₹2,734.9 Cr | Open | |
| 22 Nov 2024 | 101017580 | Others | ₹6,808.76 Cr | Open | |
| 06 Mar 2023 | 100701655 | The Hongkong and Shanghai Banking Corporation Limited | ₹9,841.76 Cr | Satisfied | |
| 03 Mar 2023 | 100692461 | Others | ₹7,947.94 Cr | Satisfied | |
| 13 Sep 2021 | 100506188 | Others | ₹200 Cr | Satisfied |
To see the full charge records of Biocon Biologics Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
Biocon Biologics Limited has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025.
Total deals
38
Secondary share transfers
22
Funding rounds
8
Convertible or debt financings
4
Acquisitions
3
Disclosed funding
₹15,829 Cr
Deals on record (5 of 38)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2025 | Secondary share transfer | Undisclosed | Buyer: Biocon Limited Seller: ADQ |
| Mar 2024 | Acquisition | ₹1,242 Cr | Buyer: Eris Lifesciences Limited Seller: Biocon Biologics Limited |
| Nov 2023 | Acquisition | ₹366 Cr | Buyer: Eris Lifesciences Limited Seller: Biocon Biologics Limited |
| Jun 2023 | Secondary share transfer | Undisclosed | Buyer: Biocon Limited Seller: Biocon Limited & Murali Krishnan |
| May 2023 | Secondary share transfer | Undisclosed | Buyer: Serum Institute Life Sciences Private Limited Seller: Biocon Pharma Limited |
To see the full deal history of Biocon Biologics Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Biocon Biologics Limited has 42 court cases on record: 38 filed by Biocon Biologics, 4 filed against it. 12 cases are pending and 30 are disposed.
Total cases
42
Filed by the company
38
Filed against the company
4
Pending
12
Disposed
30
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 31 | 0 | 7 |
| High courts | 9 | 4 | 5 |
| NCLT | 2 | 0 | 0 |
Cases on record (5 of 42)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Writ petition | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed by the company against Aadhicaizen Medicine Point (OPC) Private Limited | Pending |
| High Court of Rajasthan | Court case (SAW) | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
To see the full case history of Biocon Biologics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Biocon Biologics Limited was last rated by Icra on 10 Mar 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 10 Mar 2022 |
To see the full credit ratings and regulatory alerts of Biocon Biologics Limited, buy the company report.
MSME payment delays
Biocon Biologics Limited has 34 MSME Form 1 returns on record between 2019 and 2024, listing 28,937 overdue payments to 1,111 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 1,111)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ef Site Technologies Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Tempcon Express Private Limited | |||
| Aic Enterprises Private Limited |
To see the full MSME payment records of Biocon Biologics Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Biocon Biologics Limited has a workforce of 5,280 employees on its EPFO records as of Apr 02, 2024, across 1 active EPFO establishment.
Employee count
5,280
Active EPFO establishments
1
Employee growth
-2.15%
GST
Biocon Biologics has 21 GST registrations: 19 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
21
Active
19
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAGCB7796M2ZO | Karnataka | Active | 01 Jul 2017 |
| 29AAGCB7796M3ZN | Karnataka | Active | 23 Sep 2017 |
| 29AAGCB7796M5ZL | Karnataka | Active | 03 Jun 2019 |
| 37AAGCB7796M1ZS | Andhra Pradesh | Active | 12 Jun 2019 |
To see the full GST registrations and return filing status of Biocon Biologics Limited, buy the company report.
Recent activity
Biocon Biologics Limited has 28 board changes on record since 2016: 11 appointments and 17 cessations. The latest: Akhilesh Kumar Nand was appointed as Company Secretary on 06 Aug 2024.
AGM
Biocon Biologics Limited last Annual general meeting of members was held on 25 Jul 2025 as per latest MCA records.
Filing
Biocon Biologics Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Charges
A charge registered on 03 Mar 2023 via Charge ID 100692461 with Others was fully satisfied on 09 Jan 2025.
Charges
A charge registered on 30 Oct 2020 via Charge ID 100386601 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 07 Jan 2025.
Charges
A charge registered on 14 Dec 2018 via Charge ID 100224925 with Others was fully satisfied on 06 Jan 2025.
Charges
A charge with Others of Rs. 2,734.90 Cr registered on 09 Dec 2024 with Charge ID 101019160 was modified on 30 Dec 2024.
Charges
A charge registered on 06 Mar 2023 via Charge ID 100701655 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 17 Dec 2024.
Charges
A charge with Others amounted to Rs. 2,734.90 Cr with Charge ID 101019160 was registered on 09 Dec 2024.
Charges
A charge with Others amounted to Rs. 6,808.76 Cr with Charge ID 101017580 was registered on 22 Nov 2024.
Appointed
Akhilesh Kumar Nand was appointed as Company Secretary.
Ceased
Deepika Srivastava ceased to be Company Secretary.
Charges
A charge with Others of Rs. 7,947.94 Cr registered on 03 Mar 2023 with Charge ID 100692461 was modified on 25 Jul 2024.
36 earlier events are in the company report.
News
Frequently asked questions
Biocon Biologics is an active public limited company based in Bengaluru, Karnataka, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 08 June 2016 (10+ years old) and is registered under CIN U24119KA2016PLC093936.
Biocon Biologics has 9 current directors and KMP:
- Kiran Mazumdar Shaw - Whole-Time Director
- Bobby Kanubhai Parikh - Director
- Daniel Mark Bradbury - Director
- Rajiv Malik - Nominee Director
- Peter Baron Piot - Director
- Nivruti Rai - Director
- Arun Suresh Chandavarkar - Director
- Thomas Jason Roberts - Director
- Shreehas Pradeep Tambe - Ceo
The latest financial statements of Biocon Biologics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 25 July 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Biocon Biologics is 29AAGCB7796M2ZO, registered in Karnataka. The company has 21 GST registrations in all, of which 19 are active and 2 are cancelled or inactive. Other active GSTINs include 29AAGCB7796M3ZN (Karnataka), 29AAGCB7796M5ZL (Karnataka), 37AAGCB7796M1ZS (Andhra Pradesh).
The CIN (Corporate Identification Number) of Biocon Biologics is U24119KA2016PLC093936. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Biocon Biologics has 42 court cases on record: 38 filed by the company and 4 filed against it. 12 are pending. Most are in the district courts.
Biocon Biologics was incorporated on 08 June 2016, making it 10+ years old. It is registered with the Registrar of Companies, Bangalore.
Biocon Biologics has 38 deals on record (22 secondary share transfers, 8 funding rounds, 4 convertible or debt financings), with disclosed funding of ₹15,829 Cr; the latest was in January 2025.
The peers of Biocon Biologics by revenue are Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Hetero Labs Limited, Glenmark Pharmaceuticals Limited and 5 more, all in the Pharma industry (API Manufacturers, Biologics), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Akhilesh Kumar Nand was appointed as Company Secretary on 06 Aug 2024. Deepika Srivastava ceased to be Company Secretary on 31 Jul 2024. John Russell Fotheringham Walls ceased to be Director on 07 Jun 2024. Biocon Biologics has 28 board changes on record in total.
Biocon Biologics has 34 MSME Form 1 returns on record between 2019 and 2024, listing 28,937 overdue payments to 1,111 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Biocon Biologics can be reached through the website biocon.com. Its registered office is in Bengaluru, Karnataka, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages